COMMUNIQUÉS West-GlobeNewswire

KFSH Presents Applied Radiology AI Model at HLTH Europe 2026
15/06/2026
AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026, taking place in Amsterdam from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) is positioning radiology AI as one of the [...]
EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
15/06/2026
ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EUR neffy ® 1 mg, the first and only needle-free adrenaline treatment for anaphylaxis for [...]
CancerVax Successfully Demonstrates Full Nanoparticle Delivery in Mouse Study
15/06/2026
First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs Lehi, UT, June 15, 2026 (GLOBE NEWSWIRE) -- CancerVax Successfully Demonstrates Full Nanoparticle Delivery [...]
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
15/06/2026
BEIJING, June 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 [...]
Intravacc et SynphaBase annoncent un partenariat stratégique visant à faire progresser le développement des vaccins conjugués
15/06/2026
Les deux entreprises uniront leurs compétences complémentaires en matière d’oligosaccharides synthétiques, de développement de procédés de conjugaison et de fabrication de vaccins selon les BPF afin d’accompagner leurs [...]
Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development
15/06/2026
The companies will combine their complementary expertise in synthetic oligosaccharides, conjugation process development and GMP vaccine manufacturing to support partners developing next-generation conjugate vaccines [...]
Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity
15/06/2026
PRESS RELEASE EO2463 was well tolerated in monotherapy and in R 2 combination therapy cohorts EO2463-induced CD8 T cell expansion significantly associated with clinical response across cohorts Data support development [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
15/06/2026
COPENHAGEN, Denmark, June 15, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
15/06/2026
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 [...]
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
15/06/2026
ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) [...]
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
14/06/2026
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary [...]
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
14/06/2026
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase [...]
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
14/06/2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced [...]
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
14/06/2026
Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU Seven months after the completion of dosing (Week 76), up to 64% of patients [...]
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
14/06/2026
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – – Coordinated reductions in biomarkers of [...]
HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?
14/06/2026
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male [...]
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
14/06/2026
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the [...]
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
14/06/2026
CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble form of stem cell factor (SCF), [...]
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
14/06/2026
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026 in Amsterdam, taking place from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) will highlight that the value of [...]

Pages